OBJECTIVE: To review the current literature on posttransplant diabetes mellitus after hematopoietic stem cell transplantation, including its epidemiologic features, transplant-related risk factors, and treatment. METHODS: A literature search was conducted in PubMed for articles on diabetes mellitus after hematopoietic stem cell transplantation and effects of immunosuppressants on glucose metabolism. RESULTS: Within 2 years after hematopoietic stem cell transplantation, up to 30% of patients may have diabetes. Although some of these cases resolve, the rates of diabetes and metabolic syndrome remain elevated in comparison with those in the nontransplant patient population during long-term follow-up. Traditional risk factors for diabetes as well as features related to the transplantation process, including immunosuppressive medications, are associated with posttransplant diabetes. Cardiovascular risk also appears to be increased in this population. Limited data are available on hypoglycemic agents for posttransplant diabetes; thus, treatment decisions must be based on safety, efficacy, and tolerability, with consideration of each patient's transplant-related medications and comorbidities. CONCLUSION: Treatment of diabetes mellitus in patients who have undergone hematopoietic stem cell transplantation necessitates attention to the posttransplant medication regimen and clinical course. Although no guidelines specific to treatment of posttransplant diabetes in this patient population currently exist, treatment to goals similar to those for nontransplant patients with diabetes should be considered in an attempt to help reduce long-term morbidity and mortality.
OBJECTIVE: To review the current literature on posttransplant diabetes mellitus after hematopoietic stem cell transplantation, including its epidemiologic features, transplant-related risk factors, and treatment. METHODS: A literature search was conducted in PubMed for articles on diabetes mellitus after hematopoietic stem cell transplantation and effects of immunosuppressants on glucose metabolism. RESULTS: Within 2 years after hematopoietic stem cell transplantation, up to 30% of patients may have diabetes. Although some of these cases resolve, the rates of diabetes and metabolic syndrome remain elevated in comparison with those in the nontransplant patient population during long-term follow-up. Traditional risk factors for diabetes as well as features related to the transplantation process, including immunosuppressive medications, are associated with posttransplant diabetes. Cardiovascular risk also appears to be increased in this population. Limited data are available on hypoglycemic agents for posttransplant diabetes; thus, treatment decisions must be based on safety, efficacy, and tolerability, with consideration of each patient's transplant-related medications and comorbidities. CONCLUSION: Treatment of diabetes mellitus in patients who have undergone hematopoietic stem cell transplantation necessitates attention to the posttransplant medication regimen and clinical course. Although no guidelines specific to treatment of posttransplant diabetes in this patient population currently exist, treatment to goals similar to those for nontransplant patients with diabetes should be considered in an attempt to help reduce long-term morbidity and mortality.
Authors: Brian G Engelhardt; Shubhada M Jagasia; James E Crowe; Michelle L Griffith; Bipin N Savani; Adetola A Kassim; Pengcheng Lu; Jörn-Hendrik Weitkamp; Daniel J Moore; Sandra M Yoder; Michael T Rock; Madan Jagasia Journal: Blood Date: 2012-01-19 Impact factor: 22.113
Authors: Z DeFilipp; R F Duarte; J A Snowden; N S Majhail; D M Greenfield; J L Miranda; M Arat; K S Baker; L J Burns; C N Duncan; M Gilleece; G A Hale; M Hamadani; B K Hamilton; W J Hogan; J W Hsu; Y Inamoto; R T Kamble; M T Lupo-Stanghellini; A K Malone; P McCarthy; M Mohty; M Norkin; P Paplham; M Ramanathan; J M Richart; N Salooja; H C Schouten; H Schoemans; A Seber; A Steinberg; B M Wirk; W A Wood; M Battiwalla; M E D Flowers; B N Savani; B E Shaw Journal: Bone Marrow Transplant Date: 2016-08-22 Impact factor: 5.483
Authors: Zachariah DeFilipp; Rafael F Duarte; John A Snowden; Navneet S Majhail; Diana M Greenfield; José López Miranda; Mutlu Arat; K Scott Baker; Linda J Burns; Christine N Duncan; Maria Gilleece; Gregory A Hale; Mehdi Hamadani; Betty K Hamilton; William J Hogan; Jack W Hsu; Yoshihiro Inamoto; Rammurti T Kamble; Maria Teresa Lupo-Stanghellini; Adriana K Malone; Philip McCarthy; Mohamad Mohty; Maxim Norkin; Pamela Paplham; Muthalagu Ramanathan; John M Richart; Nina Salooja; Harry C Schouten; Helene Schoemans; Adriana Seber; Amir Steinberg; Baldeep M Wirk; William A Wood; Minoo Battiwalla; Mary E D Flowers; Bipin N Savani; Bronwen E Shaw Journal: Biol Blood Marrow Transplant Date: 2016-05-14 Impact factor: 5.742